Data from Orbit and Cosmic studies expected around the end of the yearNOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc ...

Patients are expected to continue dosing in the ongoing Phase 3 Orbit and Cosmic clinical studies. Final analyses will be conducted after patients have been on therapy for at least 18 months.

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

NOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo ...

Mereo BioPharma Group plc (NASDAQ: MREO) and Ultragenyx Pharmaceutical (NASDAQ: RARE) Inc. announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 ...

Data from Orbit and Cosmic studies expected around the end of the yearNOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc ...

Patients will continue dosing in the ongoing Phase 3 Orbit and Cosmic clinical studies with the final analyses to be conducted after patients have been on therapy for at least 18-months.

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

So for this month instead of reviewing the latest issue of Catwoman, I get to check out Selina’s wacky adventures alongside her fellow Gotham City divas in Gotham City Sirens: Unfit for Orbit #3 ...

Ultragenyx and Mereo report progress in Orbit study for setrusumab treatment of osteogenesis imperfecta in young patients.